{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:01:33Z","timestamp":1793073693915,"version":"4.5.0"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.msard.2020.102522","type":"journal-article","created":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T20:43:39Z","timestamp":1600548219000},"page":"102522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Risk of relapse in patients with neuromyelitis optica spectrum disorder: Recognition and preventive strategy"],"prefix":"10.1016","volume":"46","author":[{"given":"Xiaoyu","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4476-4016","authenticated-orcid":false,"given":"Allan G.","family":"Kermode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1187-7612","authenticated-orcid":false,"given":"Xueqiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102522_bib0001","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000640","article-title":"Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence","volume":"7","author":"Akaishi","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102522_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577236","article-title":"Risk factors of attacks in neuromyelitis optica spectrum disorders","volume":"343","author":"Akaishi","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2020.102522_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577168","article-title":"Serum AQP4-IgG level is associated with the phenotype of the first attack in neuromyelitis optica spectrum disorders","volume":"340","author":"Akaishi","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2020.102522_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116671","article-title":"Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis optica spectrum disorders (NMOSD)","volume":"410","author":"Akaishi","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2020.102522_bib0005","first-page":"901","article-title":"Elevated serum glial fibrillary acidic protein (sGFAP) is associated with increased risk of neuromyelitis optica spectrum disorder attacks in the N-MOmentum randomised, masked, placebo-controlled clinical trial of inebilizumab","volume":"252","author":"Aktas","year":"2019","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2020.102522_bib0006","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/cei.12733","article-title":"Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase","volume":"183","author":"Barros","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.msard.2020.102522_bib0007","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1590\/0004-282X20140213","article-title":"Seasonality of 278 neuromyelitis optica relapses in a Brazilian cohort","volume":"73","author":"Bichuetti","year":"2015","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.msard.2020.102522_bib0008","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/83679","article-title":"Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease","volume":"27","author":"Brenner","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.msard.2020.102522_bib0009","doi-asserted-by":"crossref","first-page":"632","DOI":"10.5588\/ijtld.13.0911","article-title":"Relapsing neuromyelitis optica temporally related to recurrent pulmonary tuberculosis","volume":"18","author":"Brey","year":"2014","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.msard.2020.102522_bib0010","doi-asserted-by":"crossref","first-page":"e1732","DOI":"10.1212\/WNL.0000000000008394","article-title":"Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica","volume":"93","author":"Burt","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102522_bib0011","first-page":"660","article-title":"Paraneoplastic neuromyelitis optica spectrum disorders: three new cases and a review of the literature","volume":"126","author":"Cai","year":"2016","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.msard.2020.102522_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167819","article-title":"Hydroxycholesterol levels in the serum and cerebrospinal fluid of patients with neuromyelitis optica revealed by LC-Ag+CIS\/MS\/MS and LC-ESI\/MS\/MS with picolinic derivatization: increased levels and association with disability during acute attack","volume":"11","author":"Cha","year":"2016","journal-title":"Plos One"},{"key":"10.1016\/j.msard.2020.102522_bib0013","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/nan.12574","article-title":"Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder","volume":"46","author":"Chang","year":"2020","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.msard.2020.102522_bib0014","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.4103\/0366-6999.189046","article-title":"Clinical features of patients with multiple sclerosis and neuromyelitis optica spectrum disorders","volume":"129","author":"Chen","year":"2016","journal-title":"Chin. Med. J. (Engl)"},{"key":"10.1016\/j.msard.2020.102522_bib0015","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fneur.2020.00035","article-title":"The detection of retina microvascular density in subclinical aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders","volume":"11","author":"Chen","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0016","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.msard.2020.102522_bib0017","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40265-018-1039-7","article-title":"Pharmacotherapy for neuromyelitis optica spectrum disorders: current management and future options","volume":"79","author":"Collongues","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.msard.2020.102522_bib0018","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1177\/1352458513515085","article-title":"Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset","volume":"20","author":"Collongues","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102522_bib0019","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2020.102522_bib0020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.addr.2014.11.007","article-title":"Biomarkers of spinal cord injury and ensuing bladder dysfunction","volume":"82-83","author":"Cruz","year":"2015","journal-title":"Adv. Drug Deliv .Rev."},{"key":"10.1016\/j.msard.2020.102522_bib0021","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1468-1331.2011.03543.x","article-title":"Monthly variation of multiple sclerosis activity in the southern hemisphere: analysis from 996 relapses in Brazil","volume":"19","author":"Damasceno","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0022","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"Jama Neurol"},{"key":"10.1016\/j.msard.2020.102522_bib0023","article-title":"Th17 Cells pathways in multiple sclerosis and neuromyelitis optica spectrum disorders: pathophysiological and therapeutic implications","volume":"2016","author":"Dos","year":"2016","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.msard.2020.102522_bib0024","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.msard.2018.11.031","article-title":"Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder (NMOSD)","volume":"27","author":"Fragoso","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102522_bib0025","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/WCO.0000000000000694","article-title":"Neuromyelitis optica spectrum disorders: still evolving and broadening","volume":"32","author":"Fujihara","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0026","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/1352458516669002","article-title":"Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"23","author":"Hakobyan","year":"2017","journal-title":"Mult. Scler."},{"issue":"s2","key":"10.1016\/j.msard.2020.102522_bib0027","first-page":"2","article-title":"Serum glial fibrillary acidic protein is elevated in a subset of neuromyelitis optica patients and associated with increased risk of attacks","volume":"22","author":"Hartung","year":"2020","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.msard.2020.102522_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.msard.2017.01.011","article-title":"Pruritus may be a common symptom related to neuromyelitis optica spectrum disorders","volume":"13","author":"He","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102522_bib0029","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105793","article-title":"Proportions of Th17 cells and Th17-related cytokines in neuromyelitis optica spectrum disorders patients: a meta-analysis","volume":"75","author":"Hou","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.msard.2020.102522_bib0031","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1212\/WNL.0000000000004611","article-title":"Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan","volume":"89","author":"Houzen","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102522_bib0032","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.msard.2018.02.022","article-title":"Short transverse myelitis in Chinese patients with neuromyelitis optica spectrum disorders","volume":"21","author":"Hu","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102522_bib0033","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jns.2016.11.054","article-title":"Pregnancy in neuromyelitis optica spectrum disorder: a multicenter study from South China","volume":"372","author":"Huang","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2020.102522_bib0034","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.msard.2020.102522_bib0035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1352458515587752","article-title":"Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints","volume":"22","author":"Jeong","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102522_bib0036","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica","volume":"81","author":"Jiao","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102522_bib0037","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica","volume":"81","author":"Jiao","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102522_bib0038","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0022-510X(00)00408-1","article-title":"Seasonal patterns in optic neuritis and multiple sclerosis: a meta-analysis","volume":"181","author":"Jin","year":"2000","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2020.102522_bib0039","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1212\/NXI.0000000000000269","article-title":"Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder","volume":"3","author":"Kessler","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102522_bib0040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-015-0387-9","article-title":"Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic","volume":"18","author":"Kessler","year":"2016","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0041","first-page":"11","article-title":"Relapse patterns in NMOSD: evidence for earlier occurrence of optic neuritis and possible seasonal variation","author":"Khalilidehkordi","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0042","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1177\/1352458516687403","article-title":"Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders","volume":"23","author":"Kim","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102522_bib0043","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.msard.2020.102522_bib0044","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.msard.2020.102522_bib0045","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1212\/WNL.0000000000004681","article-title":"High risk of postpartum relapses in neuromyelitis optica spectrum disorder","volume":"89","author":"Klawiter","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102522_bib0046","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101868","article-title":"Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder","volume":"38","author":"Kunchok","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102522_bib0048","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.msard.2020.102522_bib0049","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jneuroim.2015.02.014","article-title":"Anti-thyroid antibodies and cerebrospinal fluid findings in neuromyelitis optica spectrum disorders","volume":"281","author":"Li","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2020.102522_bib0050","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/jnnp-2017-316356","article-title":"Relapse of neuromyelitis optica associated with oral progestin","volume":"89","author":"Li","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2020.102522_bib0051","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.msard.2017.07.004","article-title":"Painful tonic spasm in neuromyelitis optica spectrum disorders: Prevalence, clinical implications and treatment options","volume":"17","author":"Liu","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102522_bib0052","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fneur.2017.00062","article-title":"Different phenotypes at onset in neuromyelitis optica spectrum disorder patients with aquaporin-4 autoimmunity","volume":"8","author":"Long","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0053","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"Jama Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0054","article-title":"Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders","volume":"39","author":"Lotan","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102522_bib0055","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1212\/NXI.0000000000000231","article-title":"Clinical utility of testing AQP4-IgG in CSF: guidance for physicians","volume":"3","author":"Majed","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102522_bib0056","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12883-015-0417-y","article-title":"Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositivepatients in a Chinese population","volume":"15","author":"Mao","year":"2015","journal-title":"Bmc Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0057","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1212\/WNL.0b013e318296e917","article-title":"Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity","volume":"80","author":"Marignier","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102522_bib0058","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.msard.2018.05.003","article-title":"Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder","volume":"23","author":"Mealy","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102522_bib0059","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1177\/1352458517730131","article-title":"Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders","volume":"24","author":"Mealy","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102522_bib0060","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.msard.2018.12.011","article-title":"Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis\/preventive treatment, MRI lesion length and presence of symptomatic brain lesions","volume":"28","author":"Mealy","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102522_bib0061","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of neuromyelitis optica in the United States: a multicenter analysis","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0062","first-page":"58","article-title":"The pathologic and diagnostic in magnetic resonance imaging of brain and cervical spine of patients with neuromyelitis optica spectrum disorder","volume":"17","author":"Mehdipour-Dastjerdi","year":"2018","journal-title":"Iran J. Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0063","first-page":"901","article-title":"Neuromyelitis optica(Devic disease) and optic-spinal form multiple sclerosis","volume":"53","author":"Miyazawa","year":"2001","journal-title":"No To Shinkei"},{"key":"10.1016\/j.msard.2020.102522_bib0064","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jns.2015.05.011","article-title":"Predictive value of MRI parameters in severity and recovery of first-episode myelitis in aquaporin-4 antibody disease","volume":"355","author":"Murchison","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2020.102522_bib0065","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/1352458512452332","article-title":"Seasonality of multiple sclerosis and neuromyelitis optica exacerbations in Japan","volume":"19","author":"Muto","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102522_bib0066","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/ene.14038","article-title":"Spinal cord involvement by atrophy and associations with disability are different between multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"27","author":"Nakamura","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0067","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1179\/1743132812Y.0000000082","article-title":"Multiple sclerosis and pain","volume":"34","author":"Nick","year":"2012","journal-title":"Neurol. Res."},{"key":"10.1016\/j.msard.2020.102522_bib0068","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0069","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1212\/WNL.0000000000002208","article-title":"Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"86","author":"Nour","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102522_bib0070","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jneuroim.2014.07.001","article-title":"Complement activation in patients with neuromyelitis optica","volume":"274","author":"Nytrova","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2020.102522_bib0071","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1212\/NXI.0000000000000334","article-title":"Microstructural visual system changes in AQP4-antibody-seropositive NMOSD","volume":"4","author":"Oertel","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102522_bib0072","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3174\/ajnr.A5141","article-title":"Enhancing brain lesions during acute optic neuritis and\/or longitudinally extensive transverse myelitis may portend a higher relapse rate in neuromyelitis optica spectrum disorders","volume":"38","author":"Orman","year":"2017","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"10.1016\/j.msard.2020.102522_bib0073","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.msard.2020.102522_bib0074","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","article-title":"Treatment of neuromyelitis optica: state-of-the-art and emerging therapies","volume":"10","author":"Papadopoulos","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0075","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.msard.2019.02.009","article-title":"Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease","volume":"30","author":"Peng","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102522_bib0076","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1212\/NXI.0000000000000061","article-title":"Disease exacerbation after rituximab induction in neuromyelitis optica","volume":"2","author":"Perumal","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102522_bib0077","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102522_bib0078","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0079","doi-asserted-by":"crossref","first-page":"e1645","DOI":"10.1212\/WNL.0000000000009245","article-title":"Evaluation of efficacy and tolerability of first-line therapies in NMOSD","volume":"94","author":"Poupart","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102522_bib0080","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0081","article-title":"Serum Neurofilament light chain in NMOSD and related disorders: comparison according to aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies status","volume":"3","author":"S","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2020.102522_bib0082","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/ana.24208","article-title":"Cerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks","volume":"76","author":"Sato","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0083","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/bjh.14534","article-title":"A phase 1\/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab","volume":"177","author":"Sawas","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.msard.2020.102522_bib0084","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1749-6632.1965.tb20235.x","article-title":"Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis","volume":"122","author":"Schumacher","year":"1965","journal-title":"Ann. N Y Acad. Sci."},{"key":"10.1016\/j.msard.2020.102522_bib0085","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaut.2009.09.013","article-title":"The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes","volume":"34","author":"Sellner","year":"2010","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.msard.2020.102522_bib0086","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1177\/1352458517735191","article-title":"Epidemiology of NMOSD in Catalonia: influence of the new 2015 criteria in incidence and prevalence estimates","volume":"24","author":"Sep\u00falveda","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102522_bib0087","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000607","article-title":"Late-onset neuromyelitis optica spectrum disorder: The importance of autoantibody serostatus","volume":"6","author":"Sepulveda","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102522_bib0088","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11940-015-0378-x","article-title":"Acute and chronic management of neuromyelitis optica spectrum disorder","volume":"17","author":"Sherman","year":"2015","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0089","doi-asserted-by":"crossref","first-page":"e1642","DOI":"10.1212\/WNL.0000000000006392","article-title":"Area postrema syndrome: frequency, criteria, and severity in AQP4-IgG-positive NMOSD","volume":"91","author":"Shosha","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102522_bib0090","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/ene.13646","article-title":"Association of serum Cystatin C with neuromyelitis optica spectrum disorders","volume":"25","author":"Shu","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0091","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1172\/JCI122942","article-title":"Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica","volume":"129","author":"Soltys","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.msard.2020.102522_bib0092","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","article-title":"Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response","volume":"88","author":"Stellmann","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2020.102522_bib0093","doi-asserted-by":"crossref","first-page":"e23489","DOI":"10.1371\/journal.pone.0023489","article-title":"The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis","volume":"6","author":"Storoni","year":"2011","journal-title":"Plos One"},{"key":"10.1016\/j.msard.2020.102522_bib0094","article-title":"Evaluation of ethnicity as a predictor of diagnostic phenotype and prognosis in neuromyelitis optica spectrum disorder in Toronto","volume":"40","author":"Stratos","year":"2020","journal-title":"Canada. Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102522_bib0095","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.msard.2017.06.008","article-title":"Gender differences among Chinese patients with neuromyelitis optica spectrum disorders","volume":"17","author":"Sun","year":"2017","journal-title":"Mult. Scler. Relat. Disord"},{"key":"10.1016\/j.msard.2020.102522_bib0096","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre","volume":"130","author":"Takahashi","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.msard.2020.102522_bib0097","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1620\/tjem.215.55","article-title":"A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica","volume":"215","author":"Takano","year":"2008","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.msard.2020.102522_bib0098","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","article-title":"Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study","volume":"75","author":"Takano","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102522_bib0099","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s12026-017-8961-8","article-title":"The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis","volume":"65","author":"Tatomir","year":"2017","journal-title":"Immunol. Res."},{"key":"10.1016\/j.msard.2020.102522_bib0100","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/832784","article-title":"Evaluation of retinal nerve fiber layer and ganglion cell complex in patients with optic neuritis or neuromyelitis optica spectrum disorders using optical coherence tomography in a Chinese cohort","author":"Tian","year":"2015","journal-title":"J. Ophthalmol."},{"key":"10.1016\/j.msard.2020.102522_bib0101","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0102","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1007\/s00415-009-5274-4","article-title":"Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis","volume":"256","author":"Uzawa","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0103","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/cen3.12024","article-title":"Role of interleukin-6 in the pathogenesis of neuromyelitis optica","volume":"4","author":"Uzawa","year":"2013","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"10.1016\/j.msard.2020.102522_bib0104","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/405837","article-title":"Relapse of neuromyelitis optica spectrum disorder associated with intravenous lidocaine","author":"Uzawa","year":"2011","journal-title":"Case Rep. Med."},{"key":"10.1016\/j.msard.2020.102522_bib0105","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/jnnp.2011.241760","article-title":"CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse","volume":"83","author":"Uzawa","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2020.102522_bib0106","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1177\/1352458518792430","article-title":"A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia","volume":"25","author":"Viswanathan","year":"2019","journal-title":"Mult Scler."},{"key":"10.1016\/j.msard.2020.102522_bib0107","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.neuint.2013.10.008","article-title":"Cerebrospinal fluid light and heavy neurofilaments in neuromyelitis optica","volume":"63","author":"Wang","year":"2013","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.msard.2020.102522_bib0108","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12883-014-0246-4","article-title":"Comparison of clinical characteristics between neuromyelitis optica spectrum disorders with and without spinal cord atrophy","volume":"14","author":"Wang","year":"2014","journal-title":"Bmc Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0109","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00415-014-7298-7","article-title":"Comparative clinical characteristics of neuromyelitis optica spectrum disorders with and without medulla oblongata lesions","volume":"261","author":"Wang","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0110","doi-asserted-by":"crossref","first-page":"e1299","DOI":"10.1212\/WNL.0000000000008160","article-title":"Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD","volume":"93","author":"Watanabe","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102522_bib0111","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000494976","article-title":"Cytokines and tissue damage biomarkers in first-onset neuromyelitis optica spectrum disorders: significance of interleukin-6","volume":"25","author":"Wei","year":"2018","journal-title":"Neuroimmunomodulat"},{"key":"10.1016\/j.msard.2020.102522_bib0112","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.msard.2020.102522_bib0113","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ana.20770","article-title":"Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis","volume":"59","author":"Weinshenker","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0114","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102522_bib0115","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102522_bib0116","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1212\/01.WNL.0000049912.02954.2C","article-title":"Neuromyelitis optica: clinical predictors of a relapsing course and survival","volume":"60","author":"Wingerchuk","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102522_bib0117","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1352458511431077","article-title":"The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease","volume":"18","author":"Wingerchuk","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102522_bib0118","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3389\/fneur.2019.01230","article-title":"Triglyceride level is an independent risk factor in first-attacked neuromyelitis optica spectrum disorders patients","volume":"10","author":"Wu","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0119","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102522_bib0120","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jns.2017.12.034","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder","volume":"385","author":"Yang","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2020.102522_bib0121","article-title":"Cerebrospinal fluid complement system biomarkers in demyelinating disease","author":"Zelek","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102522_bib0122","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12883-014-0162-7","article-title":"Neuromyelitis optica spectrum disorders without and with autoimmune diseases","volume":"14","author":"Zhang","year":"2014","journal-title":"Bmc Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0123","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/jamaneurol.2017.1336","article-title":"Safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder","volume":"74","author":"Zhang","year":"2017","journal-title":"Jama Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0124","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0125","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1177\/1352458517705479","article-title":"Aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder with recurrent short partial transverse myelitis and favorable prognosis: two new cases","volume":"23","author":"Zhang","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102522_bib0126","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s13760-017-0795-6","article-title":"Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study","volume":"117","author":"Zhang","year":"2017","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.msard.2020.102522_bib0127","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00415-019-09685-3","article-title":"Questioning the existence of monophasic neuromyelitis optica spectrum disorder by defining a novel long-term relapse-free form from a large Chinese population","volume":"267","author":"Zhang","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102522_bib0128","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jneuroim.2016.11.010","article-title":"The clinical characteristics of AQP4 antibody positive NMO\/SD in a large cohort of Chinese Han patients","volume":"302","author":"Zhangbao","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2020.102522_bib0129","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1016\/j.neuroimage.2011.11.022","article-title":"Diffusion tensor imaging characterization of occult brain damage in relapsing neuromyelitis optica using 3.0T magnetic resonance imaging techniques","volume":"59","author":"Zhao","year":"2012","journal-title":"Neuroimage"},{"key":"10.1016\/j.msard.2020.102522_bib0130","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jocn.2017.10.005","article-title":"Infections in neuromyelitis optica spectrum disorder","volume":"47","author":"Zhong","year":"2018","journal-title":"J. Clin. Neurosci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820305964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820305964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:55:53Z","timestamp":1761900953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820305964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":130,"alternative-id":["S2211034820305964"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102522","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of relapse in patients with neuromyelitis optica spectrum disorder: Recognition and preventive strategy","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102522","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102522"}}